Literature DB >> 19875292

Protective effects of tadalafil on experimental spinal cord injury in rats.

Yurdal Serarslan1, Zafer Yönden, Erkin Ozgiray, Süleyman Oktar, Eşref Oğuz Güven, Sadik Söğüt, Nebi Yilmaz, Taşkin Yurtseven.   

Abstract

Tadalafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Nitric oxide (NO) functions as a retrograde neurotransmitter in the spinal cord, and postsynaptic structures respond to NO by producing cGMP. The concentrations of cGMP in the spinal cord are controlled by the actions of PDE. The aim of the study was to evaluate and compare the effects of the use of both methylprednisolone and tadalafil on serum and tissue concentrations of NO, malondialdehyde (MDA) levels, superoxide dismutase (SOD) activity, and tissue glutathione peroxidase (GSH-Px) activity in rats with spinal cord injury (SCI). SCI was induced in Wistar albino rats by dropping a 10 g rod from a 5.0 cm height at T8-10. The 28 rats were randomly divided into four equal groups: tadalafil, methylprednisolone, non-treatment and sham groups. Rats were neurologically tested at 24 hours after trauma. At the end of the experiment, blood samples were collected and spinal cord tissue samples were harvested for biochemical evaluation. The tissue level of NO was increased in the tadalafil group compared with the non-treatment and methylprednisolone groups (p<0.05). The tissue levels of SOD and GSH-Px did not differ between the groups. Serum levels of NO were higher in the tadalafil group than in the non-treatment group (p<0.05). The increase in serum SOD levels was greater in the tadalafil group than the methylprednisolone group. Serum MDA levels in the tadalafil and methylprednisolone groups tended to be lower than in the non-treatment group (p>0.05). Tissue MDA levels in the tadalafil and methylprednisolone groups tended to be lower than in the non-treatment group and sham groups (p>0.05). Although there was no difference in neurological outcome scores between the tadalafil, methylprednisolone and non-treatment groups (p>0.05), the animals in the tadalafil and methylprednisolone groups tended to have better scores than the non-treatment group. Thus, tadalafil appears to be beneficial in reducing the effects of injury to the spinal cord by increasing tissue levels of NO and serum activity of SOD. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19875292     DOI: 10.1016/j.jocn.2009.03.036

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  18 in total

1.  Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.

Authors:  Saisudha Koka; Rakesh C Kukreja
Journal:  Mol Cell Pharmacol       Date:  2010

2.  Increased bioavailability of cyclic guanylate monophosphate prevents retinal ganglion cell degeneration.

Authors:  Lauren K Wareham; Ana C Dordea; Grigorij Schleifer; Vincent Yao; Annabelle Batten; Fei Fei; Joseph Mertz; Meredith Gregory-Ksander; Louis R Pasquale; Emmanuel S Buys; Rebecca M Sappington
Journal:  Neurobiol Dis       Date:  2018-09-10       Impact factor: 5.996

3.  Anti-apoptotic and anti-oxidative roles of quercetin after traumatic brain injury.

Authors:  Tao Yang; Bin Kong; Jian-Wen Gu; Yong-Qin Kuang; Lin Cheng; Wen-Tao Yang; Xun Xia; Hai-Feng Shu
Journal:  Cell Mol Neurobiol       Date:  2014-05-21       Impact factor: 5.046

4.  The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats.

Authors:  A Küçük; M Yucel; N Erkasap; M Tosun; T Koken; M Ozkurt; S Erkasap
Journal:  Mol Biol Rep       Date:  2012-06-27       Impact factor: 2.316

5.  Histological, morphometric, protein and gene expression analyses of rat retinas with ischaemia-reperfusion injury model treated with sildenafil citrate.

Authors:  Diogo S Zanoni; Germana A Da Silva; Raaya Ezra-Elia; Márcio Carvalho; Juliany G Quitzan; Ron Ofri; José L Laus; Renee Laufer-Amorim
Journal:  Int J Exp Pathol       Date:  2017-06       Impact factor: 1.925

6.  Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.

Authors:  Saisudha Koka; Anindita Das; Shu-Guang Zhu; David Durrant; Lei Xi; Rakesh C Kukreja
Journal:  J Pharmacol Exp Ther       Date:  2010-06-11       Impact factor: 4.030

7.  The effects of long-term administration of tadalafil on STZ-induced diabetic rats with erectile dysfunction via a local antioxidative mechanism.

Authors:  Yun Chen; Xiao-Xin Li; Hao-Cheng Lin; Xue-Feng Qiu; Jing Gao; Yu-Tian Dai; Run Wang
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

8.  The protective effect of tadalafil on IMA (ischemia modified albumin) levels in experimental renal ischemia-reperfusion injury.

Authors:  Akin Soner Amasyali; Abdullah Akkurt; Ercan Kazan; Mustafa Yilmaz; Bulent Erol; Yuksel Yildiz; Haluk Erol
Journal:  Int J Clin Exp Med       Date:  2015-09-15

9.  Renal function in a rat model of neurogenic bladder, effect of statins and phosphodiesterase-5 inhibitors.

Authors:  Iraj Mirzaii-Dizgah; Bahram Salmanyan
Journal:  Eur Spine J       Date:  2013-08-02       Impact factor: 3.134

10.  Protective and therapeutic effects of sildenafil and tadalafil on aflatoxin B1-induced hepatocellular carcinoma.

Authors:  Saurabh K Chhonker; Divya Rawat; Raj Kumar Koiri
Journal:  Mol Cell Biochem       Date:  2020-11-20       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.